12:00 AM
 | 
Nov 01, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Semuloparin: Phase III data

Top-line data from the double-blind, international Phase III SAVE-ABDO trial showed that 20 mg once-daily semuloparin for 7-10 days after surgery missed the primary endpoint of non-inferiority to 40 mg once-daily

Read the full 142 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >